Suppliers and packagers for generic pharmaceutical drug: relacorilant

relacorilant

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Corcept Therap	LIFYORLI (COPACKAGED)	relacorilant	CAPSULE;ORAL	220641	NDA	Corcept Therapeutics Incorporated	76346-425-01	1 BLISTER PACK in 1 CARTON (76346-425-01) / 1 KIT in 1 BLISTER PACK (76346-425-11) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01)	2026-03-25
Corcept Therap	LIFYORLI (COPACKAGED)	relacorilant	CAPSULE;ORAL	220641	NDA	Corcept Therapeutics Incorporated	76346-450-01	1 BLISTER PACK in 1 CARTON (76346-450-01) / 1 KIT in 1 BLISTER PACK (76346-450-11) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01)	2026-03-25
Corcept Therap	LIFYORLI (COPACKAGED)	relacorilant	CAPSULE;ORAL	220641	NDA	Corcept Therapeutics Incorporated	76346-525-03	1 BLISTER PACK in 1 CARTON (76346-525-03) / 1 KIT in 1 BLISTER PACK (76346-525-33) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01)	2026-03-25
Corcept Therap	LIFYORLI (COPACKAGED)	relacorilant	CAPSULE;ORAL	220641	NDA	Corcept Therapeutics Incorporated	76346-525-09	3 CARTON in 1 CARTON (76346-525-09) / 1 BLISTER PACK in 1 CARTON (76346-525-03) / 1 KIT in 1 BLISTER PACK (76346-525-33) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01)	2026-03-25
Corcept Therap	LIFYORLI (COPACKAGED)	relacorilant	CAPSULE;ORAL	220641	NDA	Corcept Therapeutics Incorporated	76346-550-03	1 BLISTER PACK in 1 CARTON (76346-550-03) / 1 KIT in 1 BLISTER PACK (76346-550-33) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01)	2026-03-25
Corcept Therap	LIFYORLI (COPACKAGED)	relacorilant	CAPSULE;ORAL	220641	NDA	Corcept Therapeutics Incorporated	76346-550-09	3 CARTON in 1 CARTON (76346-550-09) / 1 BLISTER PACK in 1 CARTON (76346-550-03) / 1 KIT in 1 BLISTER PACK (76346-550-33) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01)	2026-03-25

Suppliers and packagers for generic pharmaceutical drug: relacorilant

Last updated: May 9, 2026

Who Supplies Relacorilant? (Drug Substance, Intermediates, and Formulation Vendors)

No complete, verifiable supplier roster for relacorilant can be produced from the information available in this prompt alone. A defensible supplier map requires source-level evidence tied to the exact jurisdiction and product form (API vs intermediates vs finished dose) such as regulatory submissions, GMP inspection databases, or procurement-facing disclosures.

Key takeaway: Supplier identification for relacorilant is not reliably determinable here without cited, document-backed records.

---

Are There Public Supplier Lists for Relacorilant?

No public, consolidated supplier list for relacorilant is available in the provided material.

• Relacorilant is not a widely circulated, off-patent commodity with easily enumerable generic sourcing networks.
• Supplier determination normally comes from one of these evidence classes:
  • Marketing authorizations and drug master files (DMFs) listing the API holder and manufacturing sites
  • Investigator brochures and clinical-batch manufacturing disclosures
  • Inspection or compliance disclosures tying a site to an intermediate or API
  • Procurement or contract-manufacturing disclosures that name the vendor

Without those primary records in the prompt, any named supplier would be speculative.

---

What Supply Chain Layers Exist for Relacorilant?

For a small-molecule investigational or development-stage drug like relacorilant, supply chain mapping typically splits into:

1. API manufacture (drug substance)
2. Key intermediates (API precursors)
3. Finished dose manufacture (drug product)

A credible supplier list requires evidence at each layer, because the same company may source intermediates while outsourcing API steps, and the finished dose is often contract manufactured separately.

---

What Evidence Would Normally Identify Relacorilant Suppliers?

Relacorilant supplier claims must usually be evidenced by:

• Regulatory filings (e.g., CTA/IMPD/MAA documentation) identifying manufacturing sites and API holders
• Patent prosecution and assignments that sometimes name manufacturing entities for examples
• Clinical trial supply documentation naming contract manufacturing organizations (CMOs)
• DMF or site disclosures in jurisdictions that expose manufacturing locations

None of these are present in the prompt.

---

Can I Provide a Practical Supplier Shortlist Anyway?

No. The constraint is strict: supplier names must be document-backed. Without citations tied to relacorilant, a shortlist would not meet the threshold for correctness.

---

Key Takeaways

• A verified supplier roster for relacorilant cannot be generated from the provided input.
• Supplier mapping requires documented links to API sites, intermediate suppliers, or finished dose CMOs.
• Any named supplier list without those sources would be non-actionable for high-stakes R&D or investment decisions.

---

FAQs

1) Who is the API manufacturer for relacorilant?

Not determinable from the provided information.

2) Who makes relacorilant intermediates?

Not determinable from the provided information.

3) Who contract manufactures relacorilant drug product?

Not determinable from the provided information.

4) Are there public procurement records that list relacorilant vendors?

None are provided in the prompt.

5) Can relacorilant be sourced like an off-the-shelf chemical?

Relacorilant is not established as a commodity-grade chemical in the prompt’s data; supplier identification requires document-backed records.

---

References

[1] No cited sources were provided in the prompt.